Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:collaboratedWith |
gptkb:Pfizer
gptkb:Takeda gptkb:Biogen gptkb:Sanofi |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
genome editing
gene therapy |
| gptkbp:foundedIn |
1995
|
| gptkbp:founder |
gptkb:Edward_O._Lanphier
|
| gptkbp:headquartersLocation |
gptkb:Brisbane,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sangamo BioSciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
SB-525 (gene therapy for hemophilia A)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:renamed |
gptkb:Sangamo_Therapeutics
|
| gptkbp:technology |
zinc finger nucleases
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_SGMO
|
| gptkbp:website |
https://www.sangamo.com/
|
| gptkbp:bfsParent |
gptkb:TALEN_genome_editing
gptkb:ZFNs_genome_editing gptkb:TALEN gptkb:ZFN |
| gptkbp:bfsLayer |
6
|